AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins
AstraZeneca reported an 8% revenue growth in Q1, driven by strong performance in its Oncology and Rare Disease segments. The company's drugs IMFINZI and ULTOMIRIS contributed significantly to this growth. Analysts consider AZN stock a strong buy based on these results and ongoing trial data.
- ▪AstraZeneca's Oncology segment grew by 16% in Q1.
- ▪The Rare Disease segment saw a 15% increase in revenue.
- ▪The performance of IMFINZI and ULTOMIRIS was pivotal to the company's growth.
Seeking Alpha files mainly under finance. We currently carry 5,913 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908382-astrazeneca-strong-buy-8-percent-revenue-growth-q1-2026-and-wins-imfinzi-ultomiris"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
